Tirzepatide combines the actions of GLP-1 (like Semaglutide) AND GIP (glucose-dependent insulinotropic polypeptide)
Rapid injection can cause localized pain and may affect absorption consistency
The combination carries GI side effects from semaglutide (nausea, vomiting, diarrhea) plus potential naltrexone-related symptoms (dizziness, headache, insomnia) and requires liver monitoring because naltrexone can elevate enzymes
Instead, the substance is being moved into the PCAC review pipeline, where independent experts will evaluate whether it should be approved for legal compounding under Section 503A
SeekPeptides members often find that optimizing these foundational factors dramatically improves the effectiveness of any peptide protocol, not just those targeting the brain
And it is particularly limited in younger adults, because age heavily impacts the result